Biomarin Pharmaceutical Share Price Today
(NASDAQ: BMRN)

Name: Biomarin Pharmaceutical Share Price Today (NASDAQ: BMRN) - Biomarin Pharmaceutical Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Biomarin Pharmaceutical share price is $68.25 & ₹5,919.05 as on 22 Feb 2025, 2.30 'hrs' IST

$68.25

▲

-0.48

(-0.7%)

Market is closed - opens 8 PM, 24 Feb 2025

View live Biomarin Pharmaceutical share price in Dollar and Rupees. Guide to invest in Biomarin Pharmaceutical stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Biomarin Pharmaceutical, along with analyst recommendations, forecasts, and comprehensive financials.

Biomarin Pharmaceutical share price movements

Today's Low: $67.79
Today's High: $70.24
$68.25
0.68%
Downside
Day's Volatility :3.5%
Upside
2.83%
52 Weeks Low: $60.63
52 Weeks High: $94.85
$68.25
11.16%
Downside
52 Weeks Volatility :36.08%
Upside
28.04%

Biomarin Pharmaceutical (BMRN) Returns

Period	Biomarin Pharmaceutical Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	4.85%	1.6%	0.0%
6 Months	-24.15%	-5.8%	0.0%
1 Year	-24.25%	-1.0%	0.0%
3 Years	-12.5%	15.7%	-9.0%

Biomarin Pharmaceutical (BMRN) Key Statistics

in dollars & INR

Previous Close	$68.73
Open	$68.77
Today's High	$70.24
Today's Low	$67.785
Market Capitalization	$13.1B
Today's Volume	$2.2M
52 Week High	$94.85
52 Week Low	$60.63
Revenue TTM	$2.9B
EBITDA	$570.6M
Earnings Per Share (EPS)	$1.66
PE Ratio	41.4
Profit Margin	14.96%
Quarterly Earnings Growth YOY	6.39%
Return On Equity TTM	8.05%

How to invest in Biomarin Pharmaceutical Stock (BMRN) from India?

It is very easy for Indian residents to invest directly in Biomarin Pharmaceutical from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Biomarin Pharmaceutical stock in both Indian Rupees (INR) and US Dollars (USD). Search for Biomarin Pharmaceutical or BMRN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Biomarin Pharmaceutical or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Biomarin Pharmaceutical shares which would translate to 0.013 fractional shares of Biomarin Pharmaceutical as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Biomarin Pharmaceutical, in just a few clicks!

Returns in Biomarin Pharmaceutical (BMRN) for Indian investors in Rupees

The Biomarin Pharmaceutical stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Biomarin Pharmaceutical investment value today

Current value as on today

₹80,398

Returns

₹19,602

(-19.6%)

Returns from Biomarin Pharmaceutical Stock

₹24,251 (-24.25%)

Dollar Returns

₹4,649 (+4.65%)

Indian investors sentiment towards Biomarin Pharmaceutical (BMRN)

-28%

Period: Jan 24, 2025 to Feb 23, 2025. Change in 30 Days versus previous period

Search interest for Biomarin Pharmaceutical Stock from India on INDmoney has decreased by -28% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Biomarin Pharmaceutical

BlackRock Inc
11.87%
Vanguard Group Inc
10.16%
PRIMECAP Management Company
9.54%
Dodge & Cox
7.74%
Capital Research Global Investors
6.82%
Viking Global Investors LP
5.12%

Analyst Recommendation on Biomarin Pharmaceutical

Buy

74%Buy

25%Hold

0%Sell

Based on 35 Wall street analysts offering stock ratings for Biomarin Pharmaceutical(by analysts ranked 0 to 5 stars)

Based on 35 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Biomarin Pharmaceutical Stock (BMRN)

What analysts predicted

Upside of 41.49%

Target:

$96.56

Current:

$68.25

Insights on Biomarin Pharmaceutical Stock (Ticker Symbol: BMRN)

Price Movement
In the last 7 days, BMRN stock has moved up by 5.2%
Increasing Revenue
Revenue is up for the last 6 quarters, 585.96M → 747.31M (in $), with an average increase of 4.7% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 106.08M → 124.94M (in $), with an average increase of 15.1% per quarter
BMRN vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.0% return, outperforming this stock by 84.2%
BMRN vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 69.9% return, outperforming this stock by 87.2%
Price to Sales
ForBMRN every $1 of sales, investors are willing to pay $4.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

BMRN Biomarin Pharmaceutical Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$1.7B	↑ 14.27%
Net Income	$-23.8M	↓ 69.11%
Net Profit Margin	-1.4%	↑ 3.78%

	FY20	Y/Y Change
Revenue	$1.9B	↑ 9.18%
Net Income	$854.0M	↓ 3681.13%
Net Profit Margin	45.9%	↑ 47.3%

	FY21	Y/Y Change
Revenue	$1.8B	↓ 0.76%
Net Income	$-64.1M	↓ 107.5%
Net Profit Margin	-3.47%	↓ 49.37%

	FY22	Y/Y Change
Revenue	$2.1B	↑ 13.53%
Net Income	$141.6M	↓ 320.91%
Net Profit Margin	6.75%	↑ 10.22%

	FY23	Y/Y Change
Revenue	$2.4B	↑ 15.42%
Net Income	$167.6M	↑ 18.43%
Net Profit Margin	6.93%	↑ 0.18%

	FY24	Y/Y Change
Revenue	$2.9B	↑ 17.97%
Net Income	$426.9M	↑ 154.62%
Net Profit Margin	14.96%	↑ 8.03%

	Q3 FY23	Q/Q Change
Revenue	$586.0M	↓ 1.45%
Net Income	$40.4M	↓ 27.95%
Net Profit Margin	6.89%	↓ 2.53%

	Q4 FY23	Q/Q Change
Revenue	$646.2M	↑ 10.28%
Net Income	$20.4M	↓ 49.54%
Net Profit Margin	3.15%	↓ 3.74%

	Q1 FY24	Q/Q Change
Revenue	$648.8M	↑ 0.41%
Net Income	$88.7M	↑ 335.15%
Net Profit Margin	13.66%	↑ 10.51%

	Q2 FY24	Q/Q Change
Revenue	$708.7M	↑ 9.22%
Net Income	$107.2M	↑ 20.88%
Net Profit Margin	15.12%	↑ 1.46%

	Q3 FY24	Q/Q Change
Revenue	$745.7M	↑ 5.23%
Net Income	$106.1M	↓ 1.02%
Net Profit Margin	14.22%	↓ 0.9%

	Q4 FY24	Q/Q Change
Revenue	$747.3M	↑ 0.21%
Net Income	$124.9M	↑ 17.78%
Net Profit Margin	16.72%	↑ 2.5%

	FY19	Y/Y Change
Profit	$1.3B	↑ 14.34%

	FY20	Y/Y Change
Profit	$1.3B	↓ 0.62%

	FY21	Y/Y Change
Profit	$1.4B	↑ 2.96%

	FY22	Y/Y Change
Profit	$1.6B	↑ 17.2%

	FY23	Y/Y Change
Profit	$1.8B	↑ 14.25%

	FY24	Y/Y Change
Profit	$2.3B	↑ 23.42%

	Q3 FY23	Q/Q Change
Profit	$445.5M	↓ 1.19%

	Q4 FY23	Q/Q Change
Profit	$510.7M	↑ 14.63%

	Q1 FY24	Q/Q Change
Profit	$509.4M	↓ 0.27%

	Q2 FY24	Q/Q Change
Profit	$563.9M	↑ 10.71%

	Q3 FY24	Q/Q Change
Profit	$557.3M	↓ 1.17%

	Q4 FY24	Q/Q Change
Profit	$611.2M	↑ 9.67%

	FY19	Y/Y Change
Operating Cash Flow	$48.3M	↑ 138.83%
Investing Cash Flow	$-31.0M	↓ 111.74%
Financing Cash Flow	$-74.7M	↓ 80.75%

	FY20	Y/Y Change
Operating Cash Flow	$85.4M	↑ 76.88%
Investing Cash Flow	$-53.6M	↑ 72.83%
Financing Cash Flow	$181.1M	↓ 342.54%

	FY21	Y/Y Change
Operating Cash Flow	$304.5M	↑ 256.75%
Investing Cash Flow	$-366.3M	↑ 583.15%
Financing Cash Flow	$-48.0K	↓ 100.03%

	FY22	Y/Y Change
Operating Cash Flow	$175.9M	↓ 42.24%
Investing Cash Flow	$-20.0M	↓ 94.53%
Financing Cash Flow	$-18.7M	↑ 38754.17%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$70.1M	↓ 194.77%
Investing Cash Flow	$29.5M	↓ 198.39%
Financing Cash Flow	$12.0M	↓ 129.36%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$135.6M	↑ 93.61%
Investing Cash Flow	$-45.8M	↓ 255.09%
Financing Cash Flow	$-788.0K	↓ 106.59%

Biomarin Pharmaceutical Technicals Summary

Sell

Neutral

Buy

Biomarin Pharmaceutical is currently in a neutral trading position according to technical analysis indicators.

Biomarin Pharmaceutical (BMRN) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biomarin Pharmaceutical Inc.	10.56%	-24.15%	-24.25%	-12.5%	-25.18%
Biontech Se	1.58%	37.14%	28.33%	-20.32%	255.59%
Regeneron Pharmaceuticals, Inc.	3.63%	-41.61%	-29.21%	13.2%	52.94%
Vertex Pharmaceuticals Incorporated	10.15%	0.33%	11.71%	110.26%	108.69%
Alnylam Pharmaceuticals, Inc.	-10.11%	-6.89%	57.94%	61.67%	112.27%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biomarin Pharmaceutical Inc.	41.4	41.4	0.41	4.26	0.08	0.04	NA	29.66
Biontech Se	160.8	NA	0.04	-3.29	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	18.16	18.16	1.01	43.09	0.16	0.07	0.01	273.57
Vertex Pharmaceuticals Incorporated	32.84	NA	1.3	18.11	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.59	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biomarin Pharmaceutical Inc.	Buy	$13.1B	-25.18%	41.4	14.96%
Biontech Se	Buy	$28.3B	255.59%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$76.1B	52.94%	18.16	31.07%
Vertex Pharmaceuticals Incorporated	Buy	$123.3B	108.69%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$32.5B	112.27%	NA	-12.37%

About Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Organization	Biomarin Pharmaceutical
Employees	0
CEO	Mr. Alexander Hardy
Industry	Health Technology

Management People of Biomarin Pharmaceutical

Name	Title
Mr. Alexander Hardy	President, CEO & Director
Mr. Brian R. Mueller CPA	CFO & Executive VP
Dr. C. Greg Guyer Ph.D.	Executive VP & CTO
Dr. Henry J. Fuchs M.D., Ph.D.	Advisor
Ms. Erin Burkhart	Group VP & Chief Accounting Officer
Dr. Kevin Eggan Ph.D.	Chief Scientific Officer & Senior VP of Research and Early Development
Ms. Traci McCarty	Group Vice President of Investor Relations
Mr. George Eric Davis J.D.	Executive VP, Chief Legal Officer, General Counsel & Secretary
Ms. Amy Wireman	Executive VP & Chief People Officer
Dr. Ganesh Vedantham Ph.D.	Senior Vice President of Technical Development

Important FAQs about investing in BMRN Stock from India :

What is Biomarin Pharmaceutical share price today?

Biomarin Pharmaceutical share price today stands at $68.25, Open: $68.77 ; Previous Close: $68.73 ; High: $70.24 ; Low: $67.79 ; 52 Week High: $94.85 ; 52 Week Low: $60.63.

The stock opens at $68.77, after a previous close of $68.73. The stock reached a daily high of $70.24 and a low of $67.79, with a 52-week high of $94.85 and a 52-week low of $60.63.

Can Indians buy Biomarin Pharmaceutical shares?

Yes, Indians can invest in the Biomarin Pharmaceutical (BMRN) from India.

With INDmoney, you can buy Biomarin Pharmaceutical at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Biomarin Pharmaceutical at zero transaction cost.

How can I buy Biomarin Pharmaceutical shares from India?

It is very easy to buy Biomarin Pharmaceutical from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Biomarin Pharmaceutical (BMRN) be purchased?

Yes, you can buy fractional shares of Biomarin Pharmaceutical with INDmoney app.

What are the documents required to start investing in Biomarin Pharmaceutical stocks?

To start investing in Biomarin Pharmaceutical, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.